Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Intestinal Neoplasms · Gastrointestinal Neoplasms · Digestive System Neoplasms · Neoplasms by Site · Digestive System Diseases · Gastrointestinal Diseases · Colonic Diseases · Intestinal Diseases · Rectal Diseases · Colorectal Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 800 (planned)
- Started
- Dec 11, 2025
- Main results expected
- Feb 23, 2030
- Fully finished
- Aug 17, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)
Measured over: Approximately 4 years
Overall survival (OS)
Measured over: Approximately 4 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07222800 · record last updated 2026-10-08 · checked 2026-11-09 15:36 UTC